Patents by Inventor Johan BENDER

Johan BENDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID
    Publication number: 20240130981
    Abstract: The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The formulation is contained in a container. By Type IV-like, it is meant that the formulation comprises no oil, for example no triglycerides or mixed glycerides.
    Type: Application
    Filed: September 27, 2023
    Publication date: April 25, 2024
    Inventors: Jitinder WILKHU, Johan Bender
  • Pharmaceutical composition comprising a cannabinoid
    Patent number: 11806319
    Abstract: The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The formulation is contained in a container. By Type IV-like, it is meant that the formulation comprises no oil, for example no triglycerides or mixed glycerides.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: November 7, 2023
    Assignee: GW Research Limited
    Inventors: Jitinder Wilkhu, Johan Bender
  • MODIFIED RELEASE COMPOSITION COMPRISING A CANNABINOID
    Publication number: 20210059949
    Abstract: The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, or pharmaceutical composition, comprising a pharmaceutical formulation based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The oral pharmaceutical composition comprises a pharmaceutical formulation and at least one modified-release agent. By Type IV-like, it is meant that the pharmaceutical formulation comprises no oil, for example no triglycerides or mixed glycerides.
    Type: Application
    Filed: January 2, 2019
    Publication date: March 4, 2021
    Inventors: Jitinder WILKHU, Johan BENDER, Mathew COLLINS
  • ORAL PHARMACEUTICAL FORMULATION COMPRISING CANNABINOIDS AND POLOXAMER
    Publication number: 20210059976
    Abstract: The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The formulation comprises a combination of at least two cannabinoids. The first cannabinoid is selected from the group consisting of tetrahydrocannabinol (THC) and analogues thereof; and the second cannabinoid is selected from the group consisting of cannabidiol (CBD) and analogues thereof.
    Type: Application
    Filed: January 2, 2019
    Publication date: March 4, 2021
    Inventors: Jitinder WILKHU, Johan BENDER
  • PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID
    Publication number: 20210059960
    Abstract: The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The formulation is contained in a container. By Type IV-like, it is meant that the formulation comprises no oil, for example no triglycerides or mixed glycerides.
    Type: Application
    Filed: January 2, 2019
    Publication date: March 4, 2021
    Inventors: Jitinder WILKHU, Johan BENDER
  • CANNABINOID FORMULATIONS
    Publication number: 20180071210
    Abstract: The present invention relates to an oral pharmaceutical formulation comprising a cannabinoid. The formulation may take the form of a mucoadhesive gel, a tablet, a powder, a liquid gel capsule, an oral solution, granules, extrudates or injectable.
    Type: Application
    Filed: June 30, 2017
    Publication date: March 15, 2018
    Inventors: Jitinder WILKHU, Johan BENDER